The Anti-Infective Innovator Blog

Perspectives on Anti-Infective Drug Development

from Experts in the Trenches 

“Our mission at Spero is to bring novel, life improving therapies to patients suffering from infections, and there are key concepts that are unique to our field and the patients we serve. With the help of our team and key opinion leaders, we aim to amplify these topics for discussion with our collaborators within our field and in the biotech community.”    

     Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics


Recent Publications

Screen Shot 2019-06-28 at 7.23.07 PM

New Strategic Alliances to Build Industry Leading Pipeline: Partnerships with Gates MRI and the Novo REPAIR Impact Fund Validate and Accelerate Development of SPR720

July 2, 2019
By: Troy Lister

Since its founding, Spero has built strategic partnerships to advance its multi-asset, clinical-stage pipeline, raising approximately $44 million in committed non-dilutive funding since inception, with the potential to receive up to a total of $122 million in such funding, including potential milestone opportunities and full awards.

Screen Shot 2019-05-16 at 10.59.41 AM

SPR994's Value Proposition: A dive into how SPR994, an oral carbapenem, could benefit patients, payers, and investors

May 16, 2019
By: Joel Sendek

Spero has an enterprise value that does not reflect what we believe are significant market opportunities for our lead asset, an oral carbapenem SPR994, and our other product candidates.


Why Are We Losing Oral Antibiotics for the Treatment of cUTI?

March 6, 2019
By: Ian Critchley, Ph.D.

Urinary tract infections (UTI) caused by pathogens such as Escherichia coli, the most prevalent UTI pathogen, have been historically managed with oral agents including the cephalosporins, trimethoprim-sulfamethoxazole (TMP-SMX) and the fluoroquinolones. Not surprisingly, widespread use has resulted in increased resistance over time.

Designing the Right Clinical Trial

Designing the Right Clinical Trial to Yield the Greatest Value:
A Registration Trial May Provide Data for Approval, but Is It Sufficient to Answer Treatment Decisions from Healthcare Providers and Payors?

January 7, 2019
By: David Melnick, MD and Cristina Larkin

In today’s health care environment, a randomized, well-controlled trial must not only meet the requirements for approval, but just as importantly it must encourage early physician use and provide payors a justification for payment. Today, we announced positive feedback from our pre-Phase 3 FDA meeting for SPR994 for the treatment of complicated urinary tract infection (cUTI)....


Non-tuberculous Mycobacterial Disease:
The Unmet Need and a Possible New Solution with SPR720

November 5, 2018
By: Ankit Mahadevia, MD and Cristina Larkin

Non-tuberculous mycobacterial (NTM) disease is a rare, chronic infectious disease with limited treatment options that has a devastating impact on patients and their families. We at Spero are excited to announce that SPR720, our oral, broad-spectrum compound for NTM, will be entering clinical development in early 2019.


Investing in Antibiotic Companies:
Asking the Right Questions about Dose Selection Increases Probability of Clinical Success

October 1, 2018
By: Joel Sendek

As an analyst earlier in my career, one of the first stocks I ever placed a Buy rating on had the following characteristics: All the other analysts gave it a Hold rating, and it was one of the only players attempting to launch a novel product in a genericized market that most big pharmaceutical companies already abandoned. Does that sound familiar?


Spero’s New Inter-agency Collaboration:
Furthering SPR994 Development with Non-Dilutive Funding

July 16, 2018
By: Ankit Mahadevia

Today we are pleased to announce our collaboration with BARDA, DTRA and USAMRIID for the further development of our oral carbapenem product candidate SPR994.

Potentiator Platform - Banner

Advancing Spero's Potentiator Platform

May 30, 2018
By: Ankit Mahadevia and Troy Lister

The CDC estimates that every year, at least 2 million people are infected with drug resistant bacteria and that the number of deaths resulting from these infections is equivalent to one fully loaded jumbo jet crashing each week. There are many contributors to these troubling statistics, with one being a lack of novelty in the way such infections are treated.

Billion Dollar Antibioticsv2

Billion Dollar Antibiotics in the Era of Stewardship:
It is Possible by Following 3 Guiding Principles

April 25, 2018
By: Cristina Larkin, David Melnick, and Keith A. Rodvold

Can billion-dollar antibiotics and stewardship co-exist? In an era where we are seeing increasing resistance to antibiotics it seems intuitive that there would be large market opportunity for new, effective antibiotics. However, peak year sales of recent launches haven’t lived up to expectations. What has led to the seeming bifurcation of commercial success and stewardship, and how do we fix it?

De-Risking Antibiotic Drug Development with PK-PD

Antibiotic Drug Development:
Asking the Right Questions about Dose Selection Increases Probability of Clinical Success

March 26, 2018
By: Ankit Mahadevia, David Melnick, and Paul Ambrose

A recent analysis of drug development success rates from Phase I to approval found that the average infectious disease drug is 10 times more likely to succeed compared to the average oncology drug (a complementary analysis here–  different magnitude, same directionality).  Why?

-- More Publications Coming Soon --